Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / J•••••• C••••••• R•••••••• I•••

L•••••••• C•••••• Expands P••••••• C••••••• R••••••• Platform with Acquisition of J•••••• C••••••• R•••••••

Add-on acquisitionclosedadd-onannounced Sep 3, 2026closed Sep 3, 2026Fact
What happened
Target
J•••••• C••••••• R•••••••• I•••
Platform
P••••••• C••••••• R•••••••add-on basis: L•••••••• C•••••• (“LVC”) is pleased to announce that its portfolio company, P••••••• C••••••• R••••••• (“P•••••••” or the “Company”), a leading clinical trial site organization specializing in complex therapeutic areas, has acquired J•••••• C••••••• R•••••••• I••• (“J••••••”), a multi-therapeutic site based in Las Vegas, NV.
Control
Control
Share acquired
unknown
Industry
healthcare / clinic
Target location
NV, US
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
4 named
Buy side
  • R••• N••••Deal partnerconfirmed
    ““J•••••• is an excellent addition to the P••••••• network as it expands both our geographic presence and therapeutic area expertise,” said R••• N••••, Managing Partner at LVC.”
  • P••••••• C••••••• R•••••••Platformconfirmed
    “L•••••••• C•••••• (“LVC”) is pleased to announce that its portfolio company, P••••••• C••••••• R••••••• (“P•••••••” or the “Company”), a leading clinical trial site organization specializing in complex therapeutic areas, has acquired J•••••• C••••••• R•••••••• I••• (“J••••••”), a multi-therapeutic s”
  • L•••••••• C••••••Sponsorconfirmed
    “L•••••••• C•••••• (“LVC”) is pleased to announce that its portfolio company, P••••••• C••••••• R••••••• (“P•••••••” or the “Company”), a leading clinical trial site organization specializing in complex therapeutic areas, has acquired J•••••• C••••••• R•••••••• I••• (“J••••••”), a multi-therapeutic s”
Side not stated
  • J•••••• C••••••• R•••••••• I•••Targetconfirmed
    “L•••••••• C•••••• (“LVC”) is pleased to announce that its portfolio company, P••••••• C••••••• R••••••• (“P•••••••” or the “Company”), a leading clinical trial site organization specializing in complex therapeutic areas, has acquired J•••••• C••••••• R•••••••• I••• (“J••••••”), a multi-therapeutic s”
Evidence
“L•••••••• C•••••• (“LVC”) is pleased to announce that its portfolio company, P••••••• C••••••• R••••••• (“P•••••••” or the “Company”), a leading clinical trial site organization specializing in complex therapeutic areas, has acquired J•••••• C••••••• R•••••••• I••• (“J••••••”), a multi-therapeutic site based in Las Vegas, NV.”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
L•••••••• C•••••• Expands P••••••• C••••••• R••••••• Platform with Acquisition of J•••••• | Private Equity Intelligence | DFX